Ameriprise Financial Inc. Has $4.74 Million Stock Position in Guardant Health, Inc. (NASDAQ:GH)

Ameriprise Financial Inc. grew its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 96.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 155,165 shares of the company's stock after purchasing an additional 76,124 shares during the period. Ameriprise Financial Inc. owned about 0.13% of Guardant Health worth $4,739,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Guardant Health in the 4th quarter valued at $210,000. PDT Partners LLC boosted its stake in shares of Guardant Health by 9.5% in the 4th quarter. PDT Partners LLC now owns 240,473 shares of the company's stock valued at $7,346,000 after purchasing an additional 20,931 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Guardant Health in the 4th quarter valued at $863,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Guardant Health in the 4th quarter valued at $2,605,000. Finally, Nebula Research & Development LLC boosted its stake in shares of Guardant Health by 35.2% in the 4th quarter. Nebula Research & Development LLC now owns 51,845 shares of the company's stock valued at $1,584,000 after purchasing an additional 13,484 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Insider Activity

In related news, CEO Amirali Talasaz sold 106,784 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the completion of the sale, the chief executive officer now directly owns 2,202,672 shares of the company's stock, valued at approximately $107,952,954.72. This represents a 4.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 107,132 shares of company stock valued at $5,248,393 in the last ninety days. 6.10% of the stock is owned by insiders.

Guardant Health Trading Up 0.9%

Shares of GH stock traded up $0.36 on Thursday, reaching $38.55. The company had a trading volume of 966,595 shares, compared to its average volume of 2,132,465. The stock has a market cap of $4.78 billion, a PE ratio of -10.83 and a beta of 1.49. The company has a 50-day moving average of $42.79 and a 200-day moving average of $40.35. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $52.92.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The company had revenue of $203.47 million during the quarter, compared to analysts' expectations of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Guardant Health's revenue was up 20.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.46) EPS. Sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GH. Guggenheim reiterated a "buy" rating and set a $56.00 price target on shares of Guardant Health in a research report on Monday, February 24th. Morgan Stanley upped their price target on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research report on Thursday, March 6th. Stifel Nicolaus upped their price target on shares of Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Mizuho began coverage on shares of Guardant Health in a research report on Thursday, April 10th. They set an "outperform" rating and a $55.00 price target on the stock. Finally, Stephens reiterated an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a research report on Wednesday, March 26th. Twenty-one analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $52.32.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.